Skip to main content

Cognitive decline and treatment options for patients with vascular dementia

Buy Article:

$51.00 plus tax (Refund Policy)


Erkinjunti T. Cognitive decline and treatment options for patients with vascular dementia.

Acta Neurol Scand 2002: 106 (Suppl. 178): 15–18. © Blackwell Munksgaard 2002.

Cognitive impairment is the primary symptom of vascular dementia (VaD). Animal and human studies indicate that, as with Alzheimer's disease (AD), deficits in cholinergic transmission − including nicotinic receptor binding abnormalities − may be responsible for the development of cognitive impairment associated with VaD. Therefore, studies of acetylcholinesterase inhibitors (AChEIs) have been initiated and have shown promising results to date. These agents have demonstrated cognitive and global benefits in patients with VaD. Additionally, functional and behavioral benefits have been reported with the dual-mechanism AChEI galantamine. These studies suggest a potential role for AChEIs in the management of cognitive impairment associated with VaD.

Keywords: acetylcholinesterase inhibitors; cerebrovascular disease; cognition; galantamine; treatment; vascular dementia

Document Type: Research Article


Affiliations: Department of Clinical Neurology, Helsinki University Central Hospital, Helsinki, Finland

Publication date: December 1, 2002


Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more